Consenso de leucemia mieloide aguda en México

Abstract

Acute myeloid leukemia (AML) comprises a heterogeneous group of hematopoietic cell neoplasms of myeloid lineage that arise from the clonal expansion of their precursors in the bone marrow, interfering with cell differentiation, leading to a syndrome of bone marrow failure. AML is a consequence of genetic and epigenetic changes (point mutations, gene rearrangements, deletions, amplifications, and arrangements in epigenetic changes that influence gene expression) in hematopoietic precursor cells, which create a clone of abnormal cells that are capable of proliferating but cannot differentiate into mature hematopoietic cells or undergo programmed cell death. The diagnosis requires more than 20% myeloid blasts in the bone marrow and certain cytogenic abnormalities. Treatment will depend on age, comorbidities, and cytogenetic risk among the most frequent.

Fungal infections in pediatric patients with acute myeloid leukemia in a tertiary hospital

“…Little is known about IFD-related mortality rates in Latin America. However, it is known that in this region, there is a higher incidence of AML (35.5% of all acute leukemia cases in pediatric patients) compared to that in Caucasian populations (5–13% of all acute leukemia cases in pediatric patients) ( 6 – 8 ).…”